Incorporating BTK Inhibitors Therapy into Clinical Practice for the Management of B-Cell Malignancies
Incorporating BTK Inhibitors Therapy into Clinical Practice for the Management of B-Cell Malignancies
Incorporating BTK Inhibitors Therapy into Clinical Practice for the Management of B-Cell Malignancies
Incorporating BTK Inhibitors Therapy into Clinical Practice for the Management of B-Cell Malignancies
Earn Up to 2 hours of CME!
Zoom Meeting Platform
Pre-Registration is required.
Registration Fee: $25.00
The goal of this activity is to enable learners to better understand the recent data on bruton tyrosine kinase (BTK) inhibitors and how they may change practice in managing patients with B-cell malignancies (eg, chronic lymphocytic leukemia [CLL]/small lymphocytic leukemia [SLL] and mantle cell lymphoma [MCL]).